Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis.

Raskolnikov D, Brown B, Holt SK, Ball AL, Lotan Y, Strope S, Schroeck F, Ullman R, Lipman R, Smith AB, Gore JL.

J Urol. 2019 Jun 20:101097JU0000000000000399. doi: 10.1097/JU.0000000000000399. [Epub ahead of print]

PMID:
31219763
2.

The association of marital status and mortality among men with early-stage prostate cancer treated with radical prostatectomy: insight into post-prostatectomy survival strategies.

Khan S, Nepple KG, Kibel AS, Sandhu G, Kallogjeri D, Strope S, Grubb R 3rd, Wolin KY, Sutcliffe S.

Cancer Causes Control. 2019 Aug;30(8):871-876. doi: 10.1007/s10552-019-01194-y. Epub 2019 Jun 18.

PMID:
31214808
3.

Antimuscarinic use and discontinuation in an older adult population.

Vouri SM, Schootman M, Strope SA, Xian H, Olsen MA.

Arch Gerontol Geriatr. 2019 Jan - Feb;80:1-11. doi: 10.1016/j.archger.2018.09.005. Epub 2018 Sep 22.

PMID:
30268971
4.

Antimuscarinic Use in Men Treated With Bladder Outlet Obstruction Medication Therapy.

Vouri SM, Strope SA, Olsen MA, Xian H, Schootman M.

Urology. 2018 Dec;122:76-82. doi: 10.1016/j.urology.2018.08.039. Epub 2018 Sep 8.

PMID:
30205105
5.

Author Reply.

Brockman JA, Strope SA.

Urology. 2018 Jun;116:130. doi: 10.1016/j.urology.2017.12.044. Epub 2018 Apr 24. No abstract available.

PMID:
29703531
6.

Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care.

Strope SA.

Curr Opin Urol. 2018 May;28(3):262-266. doi: 10.1097/MOU.0000000000000504. Review.

PMID:
29601306
7.

Effect of a Radical Cystectomy Care Pathway on Postoperative Length of Stay and Outcomes.

Brockman JA, Vetter J, Peck V, Strope SA.

Urology. 2018 Jun;116:125-130. doi: 10.1016/j.urology.2017.12.041. Epub 2018 Mar 12.

PMID:
29545042
8.

Differential Prescribing of Antimuscarinic Agents in Older Adults with Cognitive Impairment.

Vouri SM, Schootman M, Strope SA, Birge SJ, Olsen MA.

Drugs Aging. 2018 Apr;35(4):321-331. doi: 10.1007/s40266-018-0531-9.

9.

Prostate Magnetic Resonance Imaging Provides Limited Incremental Value Over the Memorial Sloan Kettering Cancer Center Preradical Prostatectomy Nomogram.

Weaver JK, Kim EH, Vetter JM, Shetty A, Grubb RL 3rd, Strope SA, Andriole GL.

Urology. 2018 Mar;113:119-128. doi: 10.1016/j.urology.2017.10.051. Epub 2017 Dec 5.

PMID:
29217354
10.

Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist.

Rensing AJ, Kuxhausen A, Vetter J, Strope SA.

Urol Pract. 2017 May;4(3):193-199. doi: 10.1016/j.urpr.2016.07.002.

11.

Treated-and-released urinary catheterization in the emergency department by sex.

Vouri SM, Olsen MA, Theodoro D, Strope SA.

Am J Infect Control. 2017 Aug 1;45(8):905-910. doi: 10.1016/j.ajic.2017.02.025. Epub 2017 Apr 11.

12.

Mycotic Aneurysm after Bacillus Calmette-Guérin Treatment: Case Report and Review of the Literature.

Coddington ND, Sandberg JK, Yang C, Sehn JK, Kim EH, Strope SA.

Case Rep Urol. 2017;2017:4508583. doi: 10.1155/2017/4508583. Epub 2017 Feb 20.

13.

Editorial Comment.

Strope SA.

J Urol. 2017 May;197(5):1207. doi: 10.1016/j.juro.2016.12.125. Epub 2017 Feb 9. No abstract available.

PMID:
28189558
14.

Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA.

Manley BJ, Kim EH, Vetter JM, Potretzke AM, Strope SA.

Int Braz J Urol. 2017 May-Jun;43(3):432-439. doi: 10.1590/S1677-5538.IBJU.2015.0118.

15.

Author Reply.

Kim EH, Strope SA.

Urology. 2017 Apr;102:189. doi: 10.1016/j.urology.2016.08.076. Epub 2016 Dec 26. No abstract available.

PMID:
28034525
16.

Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10.

Kim EH, Weaver JK, Shetty AS, Vetter JM, Andriole GL, Strope SA.

Urology. 2017 Apr;102:183-189. doi: 10.1016/j.urology.2016.08.074. Epub 2016 Dec 2.

PMID:
27919668
17.

The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models.

Manley BJ, Tennenbaum DM, Vertosick EA, Hsieh JJ, Sjoberg DD, Assel M, Benfante NE, Strope SA, Kim E, Casuscelli J, Becerra MF, Coleman JA, Hakimi AA, Russo P.

Urol Oncol. 2017 Jan;35(1):35.e1-35.e5. doi: 10.1016/j.urolonc.2016.07.010. Epub 2016 Aug 24.

18.
19.

Editorial Comment.

Strope SA.

Urology. 2016 Apr;90:74. doi: 10.1016/j.urology.2015.10.044. Epub 2016 Feb 19. No abstract available.

PMID:
26905637
20.

Trends in the utilization of imaging for upper tract urothelial carcinoma.

Mohapatra A, Vemana G, Bhayani S, Baty J, Vetter J, Strope SA.

Urol Oncol. 2016 May;34(5):236.e23-8. doi: 10.1016/j.urolonc.2015.12.002. Epub 2016 Jan 21.

21.

Prostate Cancer, Version 1.2016.

Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.

PMID:
26733552
22.

Limited use of surveillance imaging following nephrectomy for renal cell carcinoma.

Kim EH, Vetter JM, Kuxhausen AN, Song JB, Sandhu GS, Strope SA.

Urol Oncol. 2016 May;34(5):237.e11-8. doi: 10.1016/j.urolonc.2015.11.017. Epub 2015 Dec 22.

23.

Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma.

Kim EH, Strope SA.

Urol Oncol. 2015 Dec;33(12):499-502. doi: 10.1016/j.urolonc.2015.08.008. Epub 2015 Sep 26. Review.

24.

Use of Medical Therapy and Success of Laser Surgery and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia.

Strope SA, Vetter J, Elliott S, Andriole GL, Olsen MA.

Urology. 2015 Dec;86(6):1115-22. doi: 10.1016/j.urology.2015.07.019. Epub 2015 Sep 12.

25.

Sources of variation in follow-up expenditure after radical cystectomy.

Vemana G, Vetter J, Chen L, Sandhu G, Strope SA.

Urol Oncol. 2015 Jun;33(6):267.e31-7. doi: 10.1016/j.urolonc.2015.03.009. Epub 2015 Apr 20.

26.

Comparative effectiveness research in urologic cancers.

Strope SA.

Cancer Treat Res. 2015;164:221-35. doi: 10.1007/978-3-319-12553-4_12. Review.

PMID:
25677026
27.

Ambulatory Surgery Centers and Their Intended Effects on Outpatient Surgery.

Hollenbeck BK, Dunn RL, Suskind AM, Strope SA, Zhang Y, Hollingsworth JM.

Health Serv Res. 2015 Oct;50(5):1491-507. doi: 10.1111/1475-6773.12278. Epub 2015 Jan 22.

28.

Understanding the diffusion of ambulatory surgery centers.

Suskind AM, Zhang Y, Dunn RL, Hollingsworth JM, Strope SA, Hollenbeck BK.

Surg Innov. 2015 Jun;22(3):257-65. doi: 10.1177/1553350614546004. Epub 2014 Aug 20.

29.

Prostate cancer, version 2.2014.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 May;12(5):686-718.

PMID:
24812137
30.

A population-based analysis of contemporary rates of reoperation for penile prosthesis procedures.

Grewal S, Vetter J, Brandes SB, Strope SA.

Urology. 2014 Jul;84(1):112-6. doi: 10.1016/j.urology.2014.02.028. Epub 2014 Apr 29.

31.

Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT.

Verma V, Chen L, Michalski JM, Hu Y, Zhang W, Robinson K, Verma S, Eschen L, Fergus S, Mullen D, Strope S, Grubb R 3rd, Gay HA.

World J Urol. 2015 Jan;33(1):69-75. doi: 10.1007/s00345-014-1269-6. Epub 2014 Mar 20.

PMID:
24647879
32.

Defining the potential of neoadjuvant chemotherapy use as a quality indicator for bladder cancer care.

Vemana G, Nepple KG, Vetter J, Sandhu G, Strope SA.

J Urol. 2014 Jul;192(1):43-9. doi: 10.1016/j.juro.2014.01.098. Epub 2014 Feb 8.

33.

Exploring SEER-Medicare for changes in the treatment of laryngeal cancer among elderly medicare beneficiaries.

Jean RA, Kallogjeri D, Strope SA, Hardin FM, Rich JT, Piccirillo JF.

Otolaryngol Head Neck Surg. 2014 Mar;150(3):419-27. doi: 10.1177/0194599813518186. Epub 2014 Jan 6.

PMID:
24395619
34.

Prostate cancer, version 1.2014.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2013 Dec 1;11(12):1471-9.

PMID:
24335682
35.

The impact of technology diffusion on treatment for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strope SA, Hollenbeck BK.

Med Care. 2013 Dec;51(12):1076-84. doi: 10.1097/MLR.0000000000000019.

36.

Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, Gilbert SM, Strope SA, Dunn RL, Miller DC, Hollenbeck BK.

JAMA. 2013 Jun 26;309(24):2587-95. doi: 10.1001/jama.2013.6882.

37.

Survival impact of followup care after radical cystectomy for bladder cancer.

Strope SA, Chang SH, Chen L, Sandhu G, Piccirillo JF, Schootman M.

J Urol. 2013 Nov;190(5):1698-703. doi: 10.1016/j.juro.2013.05.051. Epub 2013 May 29.

38.

Editorial comment.

Strope SA.

J Urol. 2013 Sep;190(3):922. doi: 10.1016/j.juro.2013.03.128. Epub 2013 May 29. No abstract available.

PMID:
23727077
39.

Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.

Nepple KG, Stephenson AJ, Kallogjeri D, Michalski J, Grubb RL 3rd, Strope SA, Haslag-Minoff J, Piccirillo JF, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Kibel AS.

Eur Urol. 2013 Sep;64(3):372-8. doi: 10.1016/j.eururo.2013.03.005. Epub 2013 Mar 13.

40.

Editorial comment.

Strope SA.

Urology. 2013 Mar;81(3):532. doi: 10.1016/j.urology.2012.09.057. Epub 2013 Jan 3. No abstract available.

PMID:
23290147
41.

Surgeon variation in patient quality of life after radical prostatectomy.

Hartz A, He T, Strope S, Cutler DR, Andriole G, Dechet C.

J Urol. 2013 Apr;189(4):1295-301. doi: 10.1016/j.juro.2012.10.118. Epub 2012 Oct 31.

PMID:
23123548
42.

Medicare payments for outpatient urological surgery by location of care.

Hollingsworth JM, Saigal CS, Lai JC, Dunn RL, Strope SA, Hollenbeck BK; Urologic Diseases in America Project.

J Urol. 2012 Dec;188(6):2323-7. doi: 10.1016/j.juro.2012.08.031. Epub 2012 Oct 24.

43.

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.

J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.

PMID:
22956807
44.

Surgical quality among Medicare beneficiaries undergoing outpatient urological surgery.

Hollingsworth JM, Saigal CS, Lai JC, Dunn RL, Strope SA, Hollenbeck BK; Urologic Diseases in America Project.

J Urol. 2012 Oct;188(4):1274-8. doi: 10.1016/j.juro.2012.06.031. Epub 2012 Aug 16.

45.

Evaluative care guideline compliance is associated with provision of benign prostatic hyperplasia surgery.

Strope SA, Wei JT, Smith A, Wilt TJ, Saigal CS, Elliott SP; Urologic Diseases in America Project.

Urology. 2012 Jul;80(1):84-9. doi: 10.1016/j.urology.2012.03.011. Epub 2012 May 18.

46.

Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation.

Bellinger AS, Elliott SP, Yang L, Wei JT, Saigal CS, Smith A, Wilt TJ, Strope SA; Urologic Diseases in America Project.

J Urol. 2012 May;187(5):1739-46. doi: 10.1016/j.juro.2011.12.079. Epub 2012 Mar 15.

47.

Encrusted cystitis.

Johnson MH, Strope SA.

Urology. 2012 Mar;79(3):e31-2. doi: 10.1016/j.urology.2011.12.013.

48.

Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia.

Strope SA, Yang L, Nepple KG, Andriole GL, Owens PL.

J Urol. 2012 Apr;187(4):1341-5. doi: 10.1016/j.juro.2011.11.102. Epub 2012 Feb 15.

49.

Population based analysis of the increasing incidence of kidney cancer in the United States: evaluation of age specific trends from 1975 to 2006.

Nepple KG, Yang L, Grubb RL 3rd, Strope SA.

J Urol. 2012 Jan;187(1):32-8. doi: 10.1016/j.juro.2011.09.028. Epub 2011 Nov 16.

PMID:
22088338
50.

Prostate-specific antigen-based risk assessment in younger men.

Strope SA, Andriole GL.

Eur Urol. 2012 Jan;61(1):8-9; discussion 9-10. doi: 10.1016/j.eururo.2011.08.052. Epub 2011 Sep 1. No abstract available.

PMID:
21889836

Supplemental Content

Loading ...
Support Center